Barr's Pharmaceuticals, Inc. (BRL) Shares Drop on Earnings Report and Forecast
Barr's Pharmaceuticals (NYSE: BRL) recently announced weaker-than-expected sales for the first quarter and lowered its 2008 financial forecast for the second quarter in a row. Shares of the company’s stock plunged more than 22 percent last week to $38.40 per share on the news, a new 52-week low. Quarterly revenue rose to $608 million, up from the prior year’s $597 million; however, sales of generic drugs dropped to $469 million down from $471 million last year. In addition, U.S. sales declined to $261 million from $307 million. The disappointing earnings prompted Barr Pharmaceuticals to lower its 2008 earnings forecast to…